Sotagliflozin's Efficacy & Safety in Type 1 Diabetes with CKD

THE WOODLANDS, Texas, Aug. 07, 2024 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced three significant poster presentations at the upcoming 2024 Annual Conference of the Association of Diabetes Care & Education Specialists. The conference will occur from August 9 to 12 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The posters will be on display in Exhibition Hall B from August 9 to 12. Presentations will take place on August 10, between 12:15 and 1:15 p.m. CT.

The first presentation, titled “Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease,” will be delivered by Michael J. Davies, Ph.D., Executive Director of Clinical Development at Lexicon Pharmaceuticals. This presentation will discuss the clinical effects and safety profile of sotagliflozin in individuals with Type 1 diabetes (T1D) and chronic kidney disease (CKD). 

The second poster, “Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes,” will be presented by Amy K. Carroll, Ph.D., Vice President of Medical Affairs at Lexicon Pharmaceuticals. This presentation highlights the effects of sotagliflozin when added to basal insulin therapy in patients with poorly controlled Type 2 diabetes (T2D).

The third presentation, “Patient-Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain—Learnings from In-depth Patient Interviews—Substudy of RELIEF-DPN 1,” will be presented by M. Belinda Hardin, PharmD, BCPS, Director of Medical Communications at Lexicon Pharmaceuticals. This study delves into patient-reported experiences of living with diabetic peripheral neuropathic pain (DPN) and insights gathered from detailed patient interviews.

Dr. Craig Granowitz, Lexicon’s Senior Vice President and Chief Medical Officer, expressed enthusiasm about these presentations. He emphasized the importance of the data on sotagliflozin for individuals with T1D and CKD, underscoring the high risk of progression to kidney failure and cardiovascular events in this population due to poor glycemic control. The company looks forward to engaging with diabetes educators about this crucial data.

Sotagliflozin, discovered through Lexicon’s innovative gene science approach, is an oral inhibitor of sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1), which play key roles in glucose regulation by the kidneys and gastrointestinal tract. Sotagliflozin has been evaluated in various patient populations, including those with heart failure, diabetes, and chronic kidney disease, in clinical trials involving around 20,000 patients.

Lexicon Pharmaceuticals has also developed LX9211, a potent, orally administered small molecule inhibitor targeting adaptor-associated kinase 1 (AAK1). LX9211 emerged from Lexicon’s target discovery efforts as a promising treatment for neuropathic pain. The drug has shown potential in preclinical studies, demonstrating central nervous system penetration and reduction in pain behavior without impacting opiate pathways. LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for its development in treating diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals is dedicated to pioneering transformative medicines. Through its Genome5000™ program, the company has explored the function of nearly 5,000 genes, identifying over 100 protein targets with therapeutic potential across various diseases. This precise targeting has enabled Lexicon to develop innovative treatments with significant clinical impact. The company has successfully launched INPEFA® (sotagliflozin) in the U.S. and continues to advance a strong pipeline of drug candidates targeting neuropathic pain, diabetes, metabolism, and other conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!